drugset / Trial / NCT00964912

Single Dose Study of BMS-820836

NCT00964912

Phase 1 Completed 68 enrolled Bristol-Myers Squibb
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to determine the safety and tolerability of BMS-820836 after single doses

Timeline

Start
2008-07
Primary completion
2009-04
Completion
2009-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Liafensine Small molecule 0.025 mg Oral
Comparator Liafensine Small molecule 0.1 mg Oral
Comparator Liafensine Small molecule 0.25 mg Oral
Comparator Liafensine Small molecule 0.5 mg Oral
Comparator Liafensine Small molecule 1 mg Oral
Comparator Liafensine Small molecule 2 mg Oral
Comparator Liafensine Small molecule 3 mg Oral
Comparator Liafensine Small molecule 5 mg Oral
Comparator Liafensine Small molecule 8 mg Oral

Indications